SDGR
HealthcareSchrödinger, Inc. · Medical - Healthcare Information Services · $990M
What is Schrödinger, Inc.?
Schrödinger, Inc. is a New York-based technology company that applies physics-based computational methods to accelerate drug discovery and materials science research.
Schrödinger operates two segments: Software, which licenses its computational platform to life sciences and materials science customers, and Drug Discovery, which builds an internal and collaborative pipeline of preclinical and clinical programs. Revenue comes from software subscriptions and milestone-driven collaboration agreements.
Incorporated in 1990 and headquartered in New York City, Schrödinger serves clients across biopharma, academia, and government worldwide.
- Physics-based drug discovery software platform
- Materials science computational tools
- Internal and partnered drug discovery programs
Is SDGR a Good Stock to Buy?
UQS Score rates SDGR as Poor overall.
Growth and Risk both register at a Neutral level, suggesting the business is not in acute distress and retains some forward trajectory through its software and collaboration pipeline.
Quality and Moat are both rated Weak, and Valuation is Elevated — a combination that signals meaningful headwinds for investors seeking a margin of safety.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SDGR pay dividends?
No — Schrödinger, Inc. does not currently pay a dividend.
Schrödinger does not currently pay a dividend. As an early-stage, growth-oriented company investing heavily in its software platform and drug discovery pipeline, capital is retained to fund operations and research rather than returned to shareholders.
When does SDGR report earnings?
Schrödinger reports earnings on a quarterly cadence, typical for US-listed equities.
The company's results reflect the dual nature of its business — recurring software revenue alongside lumpy, milestone-driven drug discovery income. Investors should expect variability quarter to quarter given the early-stage nature of its pipeline.
For the most recent quarter's results, visit Schrödinger's investor relations page directly.
SDGR Price History
-81.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Schrödinger, Inc.?
Based on Schrödinger, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Schrödinger do?
Schrödinger develops a physics-based computational software platform used to discover novel molecules for drug development and materials applications. It also runs an internal drug discovery operation, building a portfolio of preclinical and clinical programs through its own research and external collaborations.
Does SDGR pay dividends?
No, SDGR does not pay a dividend. The company is focused on reinvesting capital into its software platform and drug discovery pipeline rather than distributing cash to shareholders.
When does SDGR report earnings?
Schrödinger reports on a standard quarterly schedule. Because our data source does not cover specific upcoming dates, check the company's investor relations page for the latest earnings calendar.
Is SDGR a good stock to buy?
UQS Score rates SDGR as Poor, with Weak readings on both Quality and Moat, and an Elevated Valuation. Growth and Risk are Neutral. The full pillar breakdown is available to Pro members and can help investors weigh the trade-offs more precisely.
Is SDGR overvalued?
The UQS Valuation pillar for SDGR is rated Elevated, suggesting the current price is not offering a clear margin of safety relative to the company's fundamentals. Investors seeking value may find the risk-reward balance challenging at current levels.
What is SDGR's market cap bracket?
Schrödinger is classified as a small-cap stock. This places it in a category that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers in the healthcare and life sciences software space.
Is SDGR a long-term quality investment?
As a long-term quality indicator, UQS rates SDGR as Poor. Weak Quality and Moat scores suggest the business has not yet demonstrated the durable competitive advantages or financial consistency typically associated with long-term compounders. Pro members can view the complete analysis.
What sector does SDGR belong to?
Schrödinger operates in the Healthcare sector, specifically at the intersection of life sciences software and drug discovery. Its platform also serves materials science customers, giving it a cross-sector technology angle.
Unlock Full SDGR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar score
- ✓Compare SDGR against sector peers on a standardized quality framework
- ✓Track score changes over time as new data is released
Pro Analysis
SDGR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | 26.0 | 8.3 | 24.0 | 48.1 | 55.4 | 0.0 | -0.3 |
| May 12, 2026 | 26.3 | 8.3 | 24.0 | 49.5 | 55.4 | 0.0 | -0.8 |
| Apr 19, 2026 | 27.1 | 11.4 | 24.0 | 46.8 | 59.7 | 0.0 | -0.1 |
| Apr 14, 2026 | 27.2 | 11.4 | 24.0 | 47.0 | 59.7 | 0.0 | -6.5 |
| Apr 13, 2026 | 33.7 | 11.4 | 50.0 | 47.0 | 59.7 | 0.0 | +6.5 |
| Apr 2, 2026 | 27.2 | 11.4 | 24.0 | 47.0 | 59.7 | 0.0 | — |
SDGR — Pillar Breakdown
Quality
— 8.3/100 (25%)Schrödinger, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 48.1/100 (20%)Schrödinger, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 55.4/100 (15%)Schrödinger, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Schrödinger, Inc. appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Moat
— 24/100 (25%)Schrödinger, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SDGR.
Score Composition
Financial Data
More Stock Analysis
How is the SDGR UQS Score Calculated?
The UQS (Unified Quality Score) for Schrödinger, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Schrödinger, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Schrödinger, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.